Bionano Genomics (NASDAQ: BNGO) stock is experiencing a significant pre-market surge, jumping 9.83% as investors react to a groundbreaking study utilizing the company's optical genome mapping (OGM) technology.
The rally comes on the heels of an announcement regarding a new study published in The Journal of Molecular Diagnostics. The research, conducted at Lille University Hospital in France, describes an innovative method for analyzing multiple myeloma (MM) using Bionano's OGM technology, potentially overcoming longstanding challenges in the field.
Key findings from the study showcase OGM's ability to effectively analyze MM samples with as few as 0.5 million CD138-positive cells, half the typical requirement. The technology demonstrated 93% concordance with traditional FISH methods while uncovering 22 additional genetic variants. This breakthrough could streamline MM analysis, improve prognostic risk evaluation, and potentially expand the adoption of OGM in hematologic malignancy research. The positive implications for Bionano's technology in addressing unmet medical needs in blood cancer research appear to be driving investor enthusiasm in pre-market trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。